Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.esmoop.2024.103984

Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights

· 2024-11-13

24Citations

3Influential

Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of BRCA-mutated (BRCA

Links

DOI PubMed

Journal

ESMO Open

TL;DR

The long-term follow-up results from phase III trials in pretreated OC patients are discussed, which led to the Food and Drug Administration’s withdrawal of PARPi indications in this setting.

AI-generated by Semantic Scholar